Study to Assess SLN124 in Patients With Polycythemia Vera
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a
randomized placebo controlled and double-blind phase of SLN124 in adult patients with
Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK),
and Pharmacodynamic (PD) response of SLN124.